Can-Fite BioPharma (CANF) announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson. Pnina Fishman, CSO & Chairperson of Can-Fite BioPharma, commented: “We are pleased to offer this compassionate use program with Namodenoson for eligible patient in the US to address the unmet medical needs for pancreatic cancer. Initiating this program is another milestone achieved for Namodenoson, and concurrently to our ongoing Phase 2a clinical trial, as we remain committed to advancing the availability of our drug.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma’s Namodenoson Shows Promise in Liver Cancer Treatment
- Can-Fite reports disappearance of decompensated liver cirrhosis episodes
- Can-Fite BioPharma to Present Namodenoson at Upcoming BIO CEO Conference
- Can-Fite BioPharma Secures US Patent for Anti-Obesity Drug Namodenoson
- Can-Fite BioPharma announces U.S. patent office granted patent to Namodenoson
Questions or Comments about the article? Write to editor@tipranks.com